BMS-906024 is a drug with a benzodiazepine structure, developed by Bristol-Myers Squibb and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat breast, lung, colon cancers and leukemia. The drug works as an pan-Notch inhibitor. The structure is one of a set patented in 2012, and is being studied in clinical trials.
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| - BMS-906024 (en)
- BMS-906024 (it)
|
rdfs:comment
| - BMS-906024 is a drug with a benzodiazepine structure, developed by Bristol-Myers Squibb and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat breast, lung, colon cancers and leukemia. The drug works as an pan-Notch inhibitor. The structure is one of a set patented in 2012, and is being studied in clinical trials. (en)
- Il BMS-906024 è uno farmaco con struttura benzodiazepinica sviluppato dalla casa farmaceutica Bristol-Myers Squibb e presentato nella primavera 2013 durante l'American Chemical Society a New Orleans per il trattamento del cancro al seno, ai polmoni, al colon e alla leucemia. Il farmaco funziona come un inibitore di pan-Notch. La struttura fa parte di un insieme brevettato nel 2012, ed è in fase di studio. (it)
|
foaf:depiction
| |
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
thumbnail
| |
c
| |
CAS number
| |
ChemSpiderID
| |
F
| |
H
| |
IUPAC name
| - -N-[-1-Methyl-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl]-2,3-bissuccinamide (en)
|
n
| |
O
| |
PubChem
| |
SMILES
| - CN1c2ccccc2Cc3ccccc3 (en)
|
StdInChI
| |
StdInChIKey
| - AYOUDDAETNMCBW-GSHUGGBRSA-N (en)
|
UNII
| |
has abstract
| - BMS-906024 is a drug with a benzodiazepine structure, developed by Bristol-Myers Squibb and disclosed at the spring 2013 American Chemical Society meeting in New Orleans to treat breast, lung, colon cancers and leukemia. The drug works as an pan-Notch inhibitor. The structure is one of a set patented in 2012, and is being studied in clinical trials. (en)
- Il BMS-906024 è uno farmaco con struttura benzodiazepinica sviluppato dalla casa farmaceutica Bristol-Myers Squibb e presentato nella primavera 2013 durante l'American Chemical Society a New Orleans per il trattamento del cancro al seno, ai polmoni, al colon e alla leucemia. Il farmaco funziona come un inibitore di pan-Notch. La struttura fa parte di un insieme brevettato nel 2012, ed è in fase di studio. (it)
|
PubChemSubstance
| |
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
CAS number
| |
FDA UNII code
| |
PubChem
| |
foaf:isPrimaryTopicOf
| |
is Link from a Wikipage to another Wikipage
of | |
is Wikipage redirect
of | |
is foaf:primaryTopic
of | |